The rationale for advancing the formulation of azelaic acid vehicles

Cutis

Volumn 77, Issue 2 SUPPL., 2006, Pages 7-11

  Draelos, Zoe Diana ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; DERMATOLOGICAL AGENT; DICARBOXYLIC ACID;

CHEMISTRY; HUMAN; INTRADERMAL DRUG ADMINISTRATION; REVIEW; SKIN DISEASE; SOLUTION AND SOLUBILITY;

ADMINISTRATION, CUTANEOUS; CHEMISTRY, PHARMACEUTICAL; DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; HUMANS; PHARMACEUTICAL SOLUTIONS; SKIN DISEASES;

EID: 33645109356     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (4)

1. Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. Acta Derm Venereol. 1999;79:456-459.
2. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40:961-965.
3. Data on file. Montville, NJ: Intendis, Inc; 1997.
4. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845.